Similar articles

• Thrombotic risk of recombinant factor seven in pediatric cardiac surgery: a single institution experience.

  Karsies TJ, Nicol KK, Galantowicz ME, Stephens JA, Kerlin BA. Karsies TJ, et al. Ann Thorac Surg. 2010 Feb;89(2):570-6. doi: 10.1016/j.athoracsur.2009.11.023. Ann Thorac Surg. 2010. PMID: 20103344
• Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery.

  Bowman LJ, Uber WE, Stroud MR, Christiansen LR, Lazarchick J, Crumbley AJ 3rd, Kratz JM, Toole JM, Crawford FA Jr, Ikonomidis JS. Bowman LJ, et al. Ann Thorac Surg. 2008 May;85(5):1669-76; discussion 1676-7. doi: 10.1016/j.athoracsur.2008.01.089. Ann Thorac Surg. 2008. PMID: 18442563
• Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.

  Razon Y, Erez E, Vidne B, Birk E, Katz J, Tamari H, Dagan O. Razon Y, et al. Paediatr Anaesth. 2005 Mar;15(3):235-40. doi: 10.1111/j.1460-9592.2005.01429.x. Paediatr Anaesth. 2005. PMID: 15725322
• Recombinant factor VIIa: safety and efficacy.

  Goodnough LT, Shander AS. Goodnough LT, et al. Curr Opin Hematol. 2007 Sep;14(5):504-9. doi: 10.1097/MOH.0b013e32826388c3. Curr Opin Hematol. 2007. PMID: 17934358 Review.
• A retrospective case control study of recombinant factor VIIa in patients with intracranial haemorrhage caused by trauma.

  DeLoughery EP, Lenfesty B, DeLoughery TG. DeLoughery EP, et al. Br J Haematol. 2011 Mar;152(5):667-9. doi: 10.1111/j.1365-2141.2010.08437.x. Epub 2011 Jan 30. Br J Haematol. 2011. PMID: 21275948 Review. No abstract available.